Clinical Trials Logo

Clinical Trial Summary

Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05410509
Study type Interventional
Source University of Alabama at Birmingham
Contact April Riddle, BS
Phone 205-934-6504
Email ariddle@uabmc.edu
Status Recruiting
Phase N/A
Start date January 3, 2024
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Completed NCT03955393 - FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
Completed NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04687969 - Multimodal Machine Learning Characterization of Solid Tumors
Completed NCT00557609 - Phase 2 Study in Patients With MiT Tumors Phase 2
Recruiting NCT05891171 - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Phase 1
Completed NCT01235962 - A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Phase 3
Terminated NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Phase 1
Completed NCT00199888 - Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. Phase 1
Completed NCT03538028 - A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Phase 1
Terminated NCT03549000 - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Phase 1
Completed NCT02178722 - Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Phase 1/Phase 2
Completed NCT02646748 - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Phase 1
Terminated NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Terminated NCT00520533 - Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma Phase 1
Active, not recruiting NCT03260894 - Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Phase 3
Completed NCT04375150 - Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Terminated NCT03311334 - A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05909995 - Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors Phase 1
Completed NCT01666353 - PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy Early Phase 1